Issue 14.37 September 23, 2013
|
TOP STORY |
Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation Investigators tested the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation could be affected by donor killer-cell immunoglobulin-like receptor (KIR)2DL1 polymorphism. [J Clin Oncol] Abstract |
PUBLICATIONS (Ranked by impact factor of the journal) |
Thymosin β4 Increases the Potency of Transplanted Mesenchymal Stem Cells for Myocardial Repair Scientists investigated whether the cytoprotective effects of thymosin β4 can increase the effectiveness of transplanted swine mesenchymal stem cells for cardiac repair in a rat model of myocardial infarction. [Circulation] Abstract Normalization of Postinfarct Biomechanics Using a Novel Tissue-Engineered Angiogenic Construct Prostaglandin E2 Enhances Long-Term Repopulation but Does Not Permanently Alter Inherent Stem Cell Competitiveness High Resolution HLA-Matching in Hematopoietic Stem Cell Transplantation: A Retrospective Collaborative Analysis An Injectable Hydrogel Incorporating Mesenchymal Precursor Cells and Pentosan Polysulphate for Intervertebral Disc Regeneration Electrophysiological Integration and Action Potential Properties of Transplanted Cardiomyocytes Derived from Induced Pluripotent Stem Cells Periodontal Regeneration Uperiodontal Ligament Stem Cell-Transferred Amnion Interactive Effects of Cell Therapy and Rehabilitation Realize the Full Potential of Neurogenesis in Brain Injury Model |
REVIEWS |
Human Mesenchymal Stem Cells and Their Paracrine Factors for the Treatment of Brain Tumors Mesenchymal stem cells (MSCs) possess some unique features (inherent tumor tropism; anti-inflammatory and immunosuppressive properties) that are not commonly found in current anticancer agents. These cells are known to secrete a vast array of proteins including growth factors, cytokines, chemokines and so on that regulate their biology in an autocrine or paracrine manner in accordance to the surrounding microenvironment. This review briefly summarizes the biology of MSCs and discusses their properties and new development for brain cancer treatment. [Hum Gene Ther] Abstract Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field. |
SCIENCE NEWS |
‘First-in-Man’ Implant of Regenerative Cell Therapy in Parkinson’s Disease Living Cell Technologies Limited announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL® – a potential treatment for Parkinson’s disease. The pioneering brain surgery was conducted at Auckland City Hospital and the patient has recovered well so far. [Living Cell Technologies Limited] Press Release |
POLICY | ||||
Australia’s New Science-Lite Government Australia’s scientific community and incoming Prime Minister Tony Abbott are off to a rocky start. Unveiling his picks for Cabinet posts at a press conference in Canberra, Abbott left science out in the cold. Pressed by reporters on the omission, Abbott replied that Australia’s national research agency, CSIRO, would fall under the portfolio of industry minister Ian Macfarlane. [Ministry of Industry, Australia] Press Release Vote Seals Fate of Russian Academy of Sciences
|
BUSINESS |
RIKEN and Leading Indian Institutions Launch Joint Research Centers RIKEN launched two virtual Joint Research Centers with India’s premier institution the National Center for Biological Sciences, the Jawaharlal Nehru Center for Advanced Scientific research and the Indian Institute of Science. The two centers will facilitate scientific exchange and foster collaborations between Japan and India, in the fields of biology, life science and materials science. [RIKEN] Press Release Harvard’s Wyss Institute and Charité, One of Europe’s Largest University Hospitals, Announce Partnership NeoStem Reports Third Data Safety Monitoring Board Review of PreSERVE AMI Trial FDA Lifts Clinical Hold of Pluristem’s Phase II Intermittent Claudication Study ACT Files Investigational New Animal Drug (INAD) Application with FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells STEMSOFT Announces Release of New Cord Banking Software Solution NeoStem Announces Licensing of Treg Patents to Strengthen Autoimmune Platform Muscular Contusions Now Being Treated at The Center for Regenerative Medicine in Miami Using Cell Therapy |
NIH |
Office of the Director, National Institutes of Health; Notice of Closed Meetings (FR Doc No: 2013-22379) Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2013-22492) |
CBER |
2013 Biological License Application Approvals |
REGULATORY |
Food and Drug Administration (United States) |
EVENTS |
NEW Keystone Symposia: Stem Cells and Cancer February 2-7, 2014 Banff, Canada Visit our events page to see a complete list of events in the cell, gene and immunotherapy community. |
SUBSCRIBER TOOLS: | |||
Profile Center | Connexon Publications | Article Submission | Contact Us |